Abstract 116P
Background
Precision medicine, a tailored approach based on tumor profiling and actionable genetic mutations detection, is the new paradigm for oncologic patients management. An increasing number of genes is tested after new targeting drug approvals with high impacts in terms of costs and report turnaround time.
Methods
Using Diaceutics Data Repository, a global multi source database including commercial claims and laboratory data, we analyzed testing and positivity rate to compare the 2022 and 2023 diagnostic activity of the laboratory.
Results
2023 data analysis reveals NGS as the primary method used currently for the majority of tumors such as lung (90%), colorectal cancers (70%) and melanoma (78%) while in 2022 the sequential testing approach by real time PCR and FISH was the standard approach for all samples. Following the approval of new drugs in 2022, the laboratory also covers in 2023 new disease entities by NGS testing such as cholangiocarcinoma and endometrial cancer. Immunohistochemistry also encountered consistent changes: ALK5A4 antibody is now only used as a confirmatory tool for ALK gene rearrangements (previously detected by molecular testing); PAN-TRK antibody used for NTRK genes fusions screening increased and PD-L1 testing is also performed in colorectal, melanoma, head and neck squamous cancers in addition to lung adenocarcinoma.
Conclusions
Our laboratory successfully experienced a switch to NGS sequencing technology in a very short time. An automated system for library preparation was shown to be helpful for results standardization and sample tracking in a laboratory not so experienced in molecular approaches. We also demonstrated that little customized panels are suitable to detect actionable genetic alterations as recommended by International Guidelines. A parallel sequencing approach introduced in the routine of a middle size public pathology laboratory is possible and cost effective.
Editorial acknowledgement
We would like to thank Diaceutics PLC who provided data and analytic support on their DXRX platform for this research.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Role of IL6 (C-174G) polymorphism in the development of cervical intraepithelial neoplasia
Presenter: Tatyana Abakumova
Session: Cocktail & Poster Display session
Resources:
Abstract
63P - The impact of disruption of melatonin secretion on the structural-functional changes of the microbiome and the role of the melatonin-microbiome axis in the initiation of carcinogenesis
Presenter: Alexandre Tavartkiladze
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Acidosis induces ferroptosis of breast cancer via ZFAND5/SLC3A2 axis with the synergistic effect of metformin and facilitates M1 macrophage polarization
Presenter: Hanchu Xiong
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Transmembrane distribution of phosphatidylethanolamine in plasma membrane of ovarian cancer cells under conditions mimicking tumor microenvironment
Presenter: Darya Savenkova
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Metabolic regulation of GMP- and MDP-derived macrophages in glioblastoma
Presenter: Liam Wilson
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Inflammation status and sarcopenia synergistically impact outcomes in cancer patients (pt) treated with ImmunOtherapy (IO) within the framework of a Molecular Pre-screening program (MP) and a spEcial Medication (ME) program
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - The role of systemic reprogramming of GMPs in improving outcomes in glioblastoma
Presenter: Aline Atallah
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Integrated OMIC analysis reveals arginine and proline metabolism plays critical role in hypoxia-induced oral squamous cell carcinoma
Presenter: Avinash Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
70P - Individualising methotrexate dose based on MTHFR gene polymorphisms in acute lymphoblastic leukemia
Presenter: Meher Konatam
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - Single nucleotide polymorphisms in the folate metabolic pathway genes and global DNA methylation in ovarian cancer
Presenter: Sandro Surmava
Session: Cocktail & Poster Display session
Resources:
Abstract